^
Association details:
| Biomarker: | BCR-ABL1 fusion |
|---|---|
| Cancer: | Chronic Myeloid Leukemia |
| Drug: | Iclusig (ponatinib) (Multi-tyrosine kinase inhibitor) + Blincyto (blinatumomab) (CD3 agonist, CD19 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PONATINIB AND BLINATUMOMAB IN RELAPSED/REFRACTORY PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA OR CHRONIC MYELOID LEUKEMIA IN LYMPHOID BLAST PHASE: SUBGROUP ANALYSIS FROM A PHASE II TRIAL
Published date:
05/11/2023
Excerpt:
We evaluated the efficacy and safety of blinatumomab and ponatinib in pts with R/R Ph+ ALL or CML-LBP….Among the 14 pts with R/R Ph+ ALL, 1 was in CR but with detectable BCR::ABL1 at enrollment. The rate of CR/CRiwas 92% (12 of 13 pts), with CR in 11 (85%) pts....Our results show that the combination of blinatumomab and ponatinib represent an effective chemotherapy-free regimen for pts with R/R Ph+ ALL and CML-LBP, with a favorable safety profile.
